Company Description
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.
The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.
The company’s proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.
Country | United States |
Founded | 1976 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 190 |
CEO | Kara Cannon |
Contact Details
Address: 81 Executive Blvd., Suite 3 Farmingdale, New York 11735 United States | |
Phone | 631 755 5500 |
Website | enzo.com |
Stock Details
Ticker Symbol | ENZ |
Exchange | NYSE |
Fiscal Year | August - July |
Reporting Currency | USD |
CIK Code | 0000316253 |
CUSIP Number | 294100102 |
ISIN Number | US2941001024 |
Employer ID | 13-2866202 |
SIC Code | 8071 |
Key Executives
Name | Position |
---|---|
Kara Cannon | Chief Executive Officer and Director |
Patricia Eckert CPA | Chief Financial Officer |
Brian J. Fisher | General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 24, 2024 | 8-K | Current Report |
Aug 14, 2024 | 8-K | Current Report |
Aug 2, 2024 | 8-K | Current Report |
Jul 25, 2024 | 8-K | Current Report |
Jun 26, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
Jun 13, 2024 | 10-Q | Quarterly Report |
May 24, 2024 | 8-K | Current Report |
Mar 13, 2024 | 8-K | Current Report |
Mar 13, 2024 | 10-Q | Quarterly Report |
Feb 27, 2024 | 8-K | Current Report |